Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.

CONCLUSION: The identification of effective biomarkers has become a major focus in cancer research, mainly due to the necessity of selecting potentially responsive patients in order to improve their outcomes, as well as to reduce the toxicity and costs related to ineffective treatments. PMID: 30799789 [PubMed - as supplied by publisher]
Source: Current Drug Metabolism - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Metab Source Type: research

Related Links:

According to the American Cancer Society, cancer screening increases the chance of detecting certain cancers early, when they might be easier to treat. More good news from the National Cancer Institute shows that cancer survival rates are at an all-time high and cancer-related deaths are declining. Experts are attributing the improved outcomes to treatment advances, prevention awareness efforts — and screenings. Fortunately, today’s imagi ng technology provides an important tool in the fight…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
When should immunotherapy be considered in patients with NSCLC and actionable driver mutations?Annals of Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Roche today announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September - 1 October in Barcelona, Spain.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Conclusions The identification of effective biomarkers has becoming a major focus in cancer research, mainly due to the necessity of selecting potentially responsive patients in order to improve their outcomes, as well as to reduce the toxicity and costs related to ineffective treatments. This Research Topic aims to include the description of these emerging techniques and identify the most promising biomarkers in genitourinary tumors. Author Contributions RM and MS: Conception and design. AC: Drafting the manuscript. AL-B and LC: Critical revision of the manuscript and review of the literature. Conflict of Interest Sta...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ABSTRACT Cancer related to hereditary syndromes corresponds to approximately 5-10% of all tumors. Among those from the genitourinary system, many tumors had been identified to be related to genetic syndromes in the last years with the advent of new molecular genetic tests. New entities were described or better characterized, especially in kidney cancer such as hereditary leiomyomatosis renal cell carcinoma (HLRCC), succinate dehydrogenase kidney cancer (SDH-RCC), and more recently BAP1 germline mutation related RCC. Among tumors from the bladder or renal pelvis, some studies had reinforced the role of germline mutations in...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Abstract This review provides updated information published in 2014 regarding advances and major achievements in genitourinary cancer. Sections include the best in prostate cancer, renal cancer, bladder cancer, and germ cell tumors. In the field of prostate cancer, data related to treatment approach of hormone-sensitive disease, castrate-resistant prostate cancer, mechanisms of resistance, new drugs, and molecular research are presented. In relation to renal cancer, relevant aspects in the treatment of advanced renal cell carcinoma, immunotherapy, and molecular research, including angiogenesis and von Hippel-Linda...
Source: Cancer and Metastasis Reviews - Category: Cancer & Oncology Source Type: research
Conclusions Our data show that the sensitivity of AR immunohistochemistry for prostate cancer is 94.8 %. However, the specificity of AR is only 81.4 %, among our cohort of invasive genitourinary tumors. Thus, we find the specificity of AR suboptimal, yet AR may remain useful as a component of an immunostain panel.
Source: International Urology and Nephrology - Category: Urology & Nephrology Source Type: research
Slideset - Brian Rini, MD, FACP, and Nicholas J. Vogelzang, MD, provide expert perspective on the clinical applicability of key study findings in prostate cancer, renal cell carcinoma, bladder cancer, and germ cell tumors.
Source: Clinical Care Options Prostate Cancer - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Cytology | Drugs & Pharmacology | Germ Cell Tumors | Kidney Cancer | Pathology | Prostate Cancer | Renal Cell Carcinoma | Toxicology